Novartis (NOVN) Given a CHF 96 Price Target by Deutsche Bank Analysts

Share on StockTwits

Novartis (VTX:NOVN) has been assigned a CHF 96 target price by investment analysts at Deutsche Bank in a research report issued on Friday. The firm presently has a “neutral” rating on the stock.

Several other research firms also recently weighed in on NOVN. UBS Group set a CHF 82 price target on shares of Novartis and gave the stock a “neutral” rating in a research note on Wednesday, November 21st. Goldman Sachs Group set a CHF 110 price target on shares of Novartis and gave the stock a “buy” rating in a research note on Monday, November 19th. HSBC set a CHF 84 price target on shares of Novartis and gave the stock a “neutral” rating in a research note on Thursday, October 25th. JPMorgan Chase & Co. set a CHF 87 price target on shares of Novartis and gave the stock a “neutral” rating in a research note on Monday, October 22nd. Finally, Credit Suisse Group set a CHF 86 price target on shares of Novartis and gave the stock a “neutral” rating in a research note on Friday, October 19th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of CHF 91.40.

Novartis has a 52 week low of CHF 72.45 and a 52 week high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Further Reading: How do taxes affect a CDs total return?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Brokerages Anticipate Repligen Co.  Will Post Quarterly Sales of $50.33 Million
Zacks: Brokerages Anticipate Repligen Co. Will Post Quarterly Sales of $50.33 Million
Stealth 24-Hour Volume Tops $138.00
Stealth 24-Hour Volume Tops $138.00
Molecular Future  1-Day Volume Tops $421,889.00
Molecular Future 1-Day Volume Tops $421,889.00
Deutsche Lufthansa AG  Receives Consensus Recommendation of “Hold” from Brokerages
Deutsche Lufthansa AG Receives Consensus Recommendation of “Hold” from Brokerages
Heat Biologics  Trading Down 4.3%
Heat Biologics Trading Down 4.3%
Tyme Technologies  Sees Unusually-High Trading Volume
Tyme Technologies Sees Unusually-High Trading Volume


Leave a Reply

© 2006-2019 Ticker Report